EDUCATION
Stopping Trials Early for Benefit: Overestimating Effects and Putting Patients at Risk .
Stopping randomized trials early may offer time and cost savings, quicker market access, and faster patient access to promising treatments. However, trials halted prematurely often overestimate treatment effects due to random variability in early outcomes and insufficient sample sizes. Systematic reviews show that many such trials lack transparent reporting of key details like sample size targets, stopping rules, and interim analysis timing, inevitably raising concerns over reliability. Consequently, these trials frequently prompt replication efforts, reflecting skepticism in the clinical community. Caution and transparency are essential when interpreting results from trials stopped early for benefit.
Already have an account? Log in
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
